Turtle Creek Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$501K Buy
1,009
+71
+8% +$31.5K 0.03% 262
2026
Q1
$419K Buy
938
+215
+30% +$100K 0.03% 262
2025
Q4
$328K Buy
723
+70
+11% +$30.2K 0.03% 287
2025
Q3
$256K Sell
653
-124
-16% -$51.8K 0.02% 306
2025
Q2
$346K Buy
+777
New +$358K 0.04% 202
2024
Q1
Sell
-255
Closed -$104K 799
2023
Q4
$104K Buy
+255
New +$94.2K 0.03% 195

Other funds holding VRTX

Turtle Creek Wealth Advisors's VRTX Position: Q2 2026 in Review

Turtle Creek Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 7.6% in Q2 2026, buying an estimated $31.5K and bringing the position to 1,009 shares worth $501K. The position accounts for 0.03% of the portfolio, ranked #262.

Turtle Creek Wealth Advisors first reported a position in VRTX in Q4 2023 and has held it in 6 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Turtle Creek Wealth Advisors held 1,009 shares of Vertex Pharmaceuticals worth $501K as of Q2 2026.
  • Turtle Creek Wealth Advisors bought 71 Vertex Pharmaceuticals shares in Q2 2026, an estimated $31.5K.
  • Vertex Pharmaceuticals made up 0.03% of Turtle Creek Wealth Advisors's portfolio in Q2 2026, its #262 holding.
  • Turtle Creek Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Turtle Creek Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.